Scarica l'app Stockscreener
295.54
0.99%
-2.96
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$298.50
Aprire:
$297.67
Volume 24 ore:
164.50K
Relative Volume:
0.73
Capitalizzazione di mercato:
$5.89B
Reddito:
$274.48M
Utile/perdita netta:
$153.56M
Rapporto P/E:
40.07
EPS:
7.3755
Flusso di cassa netto:
$114.06M
1 W Prestazione:
-2.08%
1M Prestazione:
+7.39%
6M Prestazione:
+32.39%
1 anno Prestazione:
+63.49%
Intervallo 1D:
$292.56
$297.67
Intervallo di 1 settimana:
$292.28
$311.86
Portata 52W:
$175.89
$326.63
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
295.54 | 5.89B | 274.48M | 153.56M | 114.06M | 7.3755 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-09-25 | Iniziato | Barclays | Overweight |
| 2026-08-14 | Iniziato | Leerink Partners | Outperform |
| 2026-07-21 | Ripresa | Citigroup | Buy |
| 2026-03-11 | Iniziato | BofA Securities | Buy |
| 2025-12-09 | Iniziato | Citigroup | Buy |
| 2025-04-10 | Iniziato | Stifel | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Ligand Pharma CLO Andrew Reardon sells $1.52 million in stock By Investing.com - Investing.com South Africa
Ligand Pharma CLO Andrew Reardon sells $1.52 million in stock - Investing.com
Form 4 Ligand Pharmaceuticals Incorporated For: 11 October By Investing.com - Investing.com Canada
Ligand Pharmaceuticals Incorpor (LGND) Stock forecasts - Yahoo Finance UK
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call - Benzinga
Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call - Benzinga
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo! Finance Canada
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
Ligand Pharmaceuticals (LGND) Stock May Be 27% Undervalued After A New Royalty Deal - Yahoo Finance
Is Ligand Pharmaceuticals (LGND) Below Fair Value As It Funds AvenCell? - Yahoo Finance
Is Ligand Pharmaceuticals (LGND) Using AvenCell CAR-T Royalties To Redefine Its Cash-Flow Playbook? - Yahoo Finance
Form 4 Ligand Pharmaceuticals Incorporated For: 28 September By Investing.com - Investing.com Nigeria
Ligand (LGND)-AvenCell Deal: Most of the Funding Is Tied to Milestones - Yahoo Finance
Barclays Initiates Outperform on Ligand Pharmaceuticals (LGND) w - GuruFocus
Ligand Pharma a new Outperform at Barclays on biopharma royalty aggregation - TradingView
Barclays initiates Ligand Pharma stock with overweight rating - Investing.com
Barclays Initiates Ligand Pharmaceuticals at Overweight With $345 Price Target - Yahoo Finance
US53220KAJ7 Bond Profile: Coupon and Redemption - TradingView
Ligand Pharmaceuticals Invests Up to $47 Million in AvenCell - Yahoo Finance
Ligand and AvenCell Therapeutics Enter Financing Agreement - GlobeNewswire
Ligand Pharmaceuticals Incorpor (LGND) Stock Forecasts - Yahoo Finance
McDermott Will & Schulte advises Ligand Pharmaceuticals in $23 million acquisition of royalty and milestone interest in Santen’s Ryjunea® - McDermott Will & Schulte
Ligand Pharmaceuticals Acquires Ryjunea Royalty Interest for $23 Million - Yahoo Finance
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea® - Yahoo Finance
Ligand Pharmaceuticals: The Multiple Is The Whole Bet; Hold - Seeking Alpha
A Ligand (NASDAQ: LGND) director is planning a stock sale; the filing shows how big - Stock Titan
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Australia
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Nigeria
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Australia
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (LGND) Rides Royalty Growth Hopes, Is The Stock Still Undervalued? - simplywall.st
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com South Africa
Ligand Pharmaceuticals CLO Reardon sells $1.43m in stock By Investing.com - Investing.com UK
Ligand Pharmaceuticals Incorporated (LGND) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
ETFs Investing in Ligand Pharmaceuticals Incorporated Stocks - TradingView
Ligand Pharmaceuticals (LGND): Massive XOMA Acquisition Doubles The Royalty Book - Yahoo Finance
Ligand (NASDAQ: LGND) insider to sell 15,000 shares after plan trades - Stock Titan
XOMA Royalty Reports $41.2M First-Half Net Loss on Trial Failures - Minichart
If You Invested $100 In Ligand Pharmaceuticals Stock 5 Years Ago, You Would Have This Much Today - Benzinga
A cash-heavy royalty arm at Ligand (NASDAQ: LGND) is loss-making - Stock Titan
Price to earnings forward of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Enterprise value to EBITDA forward of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals at Midwest IDEAS: royalty model gains scale By Investing.com - Investing.com Canada
Ligand to Participate in September Investor Conferences - marketscreener.com
Ligand executives will meet investors at three September events - Stock Titan
Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital - Yahoo Finance
Ligand (LGND) Snapshot: Ends Down by 2.13% at $280.18 for the Current Session; Price Setup: the Supplied Trading Band Runs From $266.17 to $294.19 at the CloseEarnings Breakout Stocks - vinanet.vn
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ligand Pharmaceuticals Inc Azioni (LGND) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Reardon Andrew | CLO & Secretary |
Oct 02 '26 |
Sale |
304.07 |
5,000 |
1,520,346 |
31,854 |
| Zimmermann Martine | Director |
Sep 10 '26 |
Sale |
285.00 |
1,200 |
342,000 |
3,897 |
| MARTINE ZIMMERMANN | Director |
Sep 10 '26 |
Proposed Sale |
285.00 |
1,200 |
342,000 |
0 |
| ANDREW REARDON | Officer |
Sep 03 '26 |
Proposed Sale |
286.92 |
15,000 |
4,303,800 |
0 |
| Reardon Andrew | CLO & Secretary |
Sep 03 '26 |
Sale |
286.09 |
5,000 |
1,430,434 |
36,514 |
| Haas Jason | Director |
Aug 12 '26 |
Sale |
292.81 |
7,138 |
2,090,062 |
3,981 |
| Haas Jason | Director |
Aug 12 '26 |
Option Exercise |
51.56 |
6,138 |
316,475 |
11,119 |
| Espinoza Octavio | Chief Financial Officer |
Aug 12 '26 |
Option Exercise |
56.91 |
31,641 |
1,800,574 |
59,337 |
| OCTAVIO ESPINOZA | Officer |
Aug 12 '26 |
Proposed Sale |
288.75 |
31,641 |
9,136,339 |
0 |
| Jason Haas | Director |
Aug 12 '26 |
Proposed Sale |
292.81 |
7,138 |
2,090,062 |
0 |
2.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):